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Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of
synthetic ceramide analogues
Abstract
Inhibition of GSL (glycosphingolipid) synthesis reduces Aβ (amyloid β-peptide) production in vitro.
Previous studies indicate that GCS (glucosylceramide synthase) inhibitors modulate phosphorylation of
ERK1/2 (extracellular-signal-regulated kinase 1/2) and that the ERK pathway may regulate some aspects
of Aβ production. It is not clear whether there is a causative relationship linking GSL synthesis inhibition,
ERK phosphorylation and Aβ production. In the present study, we treated CHO cells (Chinese-hamster
ovary cells) and SH-SY5Y neuroblastoma cells, that both constitutively express human wild-type APP
(amyloid precursor protein) and process this to produce Aβ, with GSL-modulating agents to explore this
relationship. We found that three related ceramide analogue GSL inhibitors, based on the PDMP (Dthreo-1-phenyl-2-decanoylamino- 3-morpholino-1-propanol) structure, reduced cellular Aβ production and
in all cases this was correlated with inhibition of pERK (phosphorylated ERK) formation. Importantly, the
L-threo enantiomers of these compounds (that are inferior GSL synthesis inhibitors compared with the Dthreo-enantiomers) also reduced ERK phosphorylation to a similar extent without altering Aβ production.
Inhibition of ERK activation using either PD98059 [2-(2-amino-3-methoxyphenyl)-4H- 1-benzopyran-4-one]
or U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene) had no impact on Aβ
production, and knockdown of endogenous GCS using small interfering RNA reduced cellular GSL levels
without suppressing Aβ production or pERK formation. Our data suggest that the alteration in pERK levels
following treatment with these ceramide analogues is not the principal mechanism involved in the
inhibition of Aβ generation and that the ERK signalling pathway does not play a crucial role in processing
APP through the amyloidogenic pathway.
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Inhibition of GSL (glycosphingolipid) synthesis reduces Aβ (amyloid β-peptide) production
in vitro. Previous studies indicate that GCS (glucosylceramide synthase) inhibitors modulate
phosphorylation of ERK1/2 (extracellular-signal-regulated kinase 1/2) and that the ERK pathway
may regulate some aspects of Aβ production. It is not clear whether there is a causative relationship
linking GSL synthesis inhibition, ERK phosphorylation and Aβ production. In the present study,
we treated CHO cells (Chinese-hamster ovary cells) and SH-SY5Y neuroblastoma cells, that
both constitutively express human wild-type APP (amyloid precursor protein) and process this
to produce Aβ, with GSL-modulating agents to explore this relationship. We found that three
related ceramide analogue GSL inhibitors, based on the PDMP (D-threo-1-phenyl-2-decanoylamino3-morpholino-1-propanol) structure, reduced cellular Aβ production and in all cases this was
correlated with inhibition of pERK (phosphorylated ERK) formation. Importantly, the L-threo
enantiomers of these compounds (that are inferior GSL synthesis inhibitors compared with the
D-threo-enantiomers) also reduced ERK phosphorylation to a similar extent without altering Aβ
production. Inhibition of ERK activation using either PD98059 [2-(2-amino-3-methoxyphenyl)-4H1-benzopyran-4-one] or U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene)
had no impact on Aβ production, and knockdown of endogenous GCS using small interfering
RNA reduced cellular GSL levels without suppressing Aβ production or pERK formation. Our
data suggest that the alteration in pERK levels following treatment with these ceramide analogues is
not the principal mechanism involved in the inhibition of Aβ generation and that the ERK signalling
pathway does not play a crucial role in processing APP through the amyloidogenic pathway.

Key words: Alzheimer’s disease, amyloid β-peptide, amyloid precursor protein, extracellular-signal-regulated kinase (ERK),
glycosphingolipid.
Abbreviations: 2AA, 2-anthranilic acid; Aβ, amyloid β-peptide; Aβ40, Aβ-(1–40); Aβ42, Aβ-(1–42); AD, Alzheimer’s disease;
APP, amyloid precursor protein; BACE-1, β-site APP-cleaving enzyme; CHO cell, Chinese-hamster ovary cell; DAPT, N[N-(3,5-difluorophenacetyl)-l-alanyl]-(S)-phenylglycine t-butyl ester; ERK, extracellular-signal-regulated kinase; EtDO-P4, dthreo-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol; FBS, fetal bovine serum; GAPDH, glyceraldehyde3-phosphate dehydrogenase; GCS, glucosylceramide synthase; GlcCer, glucosylceramide; GSL, glycosphingolipid; LacCer,
lactosylceramide; MAPK, mitogen-activated protein kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-2H-tetrazolium bromide;
PDMP, d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol; pERK, phosphorylated ERK; PPMP, d-threo-1-phenyl2-hexadecanoylamino-3-morpholino-1-propanol; PS, presenilin; sAPPα, soluble APPα fragment; siRNA, small interfering RNA.
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INTRODUCTION
Amyloid plaques are a key pathological feature of AD
(Alzheimer’s disease) [1], a common neurodegenerative
disorder affecting our aging population. Amyloid plaques
are enriched with Aβ (amyloid β-peptide) peptides that
are derived from the proteolytic processing of the APP
(amyloid precursor protein) [2]. APP can be proteolytically processed by the α-secretase pathway that does not
generate Aβ as the metalloproteases [such as ADAM10 (a disintegrin and metalloproteinase 10)] responsible
cleave in the middle of the Aβ sequence. In an alternative pathway, sequential cleavage of APP by β-secretase
[BACE-1 (β-site APP-cleaving enzyme)] and γ -secretase
[a complex containing PS-1 (presenilin 1) or PS-2 as
the catalytic subunit] generates neurotoxic Aβ peptides
predominantly of 40 or 42 amino acids [3–6]. In addition
to factors that regulate the rate of Aβ production, the
ratio of Aβ40 [Aβ-(1–40)] to Aβ42 [Aβ-(1–42)] species
generated, their propensity to form macromolecular
complexes and their catabolism and clearance from the
central nervous system are all relevant therapeutic targets
for AD [3,7]. Despite the recognized role for Aβ in AD
neurodegeneration, the factors that modify Aβ production and deposition are not completely understood.
Previous studies have suggested that specific GSLs
(glycosphingolipids) may promote Aβ production
and/or its assembly into neurotoxic complexes [8–13].
GSLs co-localize with Aβ in amyloid plaques and it has
been proposed that ganglioside GM1 interacts with Aβ
to form a seed for amyloid plaque formation [14]. Other
studies have shown that GM1 can act on mature Aβ fibrils
in amyloid plaque to regenerate neurotoxic Aβ protofibrils [15]. In addition, when GD3 synthase-knockout
mice (phenotype characterized by reductions in the
levels of several brain gangliosides) were crossed with
APPswe + PSEN1DE9 amyloidogenic mice (a mouse
model of AD displaying both amyloid plaque pathology
and cognitive impairments), both soluble Aβ and plaque
load were reduced (85–95 %) and this was associated with
improved cognitive performance [16]. These data imply
that pharmacological inhibition of GSL synthesis may be
beneficial in the AD/amyloidogenesis context.
A previous study has shown that the GSL synthesis
inhibitor PDMP (d-1-phenyl-2-decanoylamino-3morpholino-1-propanol) reduced Aβ secretion from
SH-SY5Y neuroblastoma cells by ∼ 55 % when used
at a concentration of 25 μM for a 48 h period [10]. In
recent studies, we have shown that two more potent
GSL synthesis inhibitors, PPMP (d-threo-1-phenyl2-hexadecanoylamino-3-morpholino-1-propanol) and
EtDO-P4
(d-threo-ethylenedioxy-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol),
inhibit
Aβ
secretion both from CHO cells (Chinese-hamster ovary
cells) stably expressing human APP695 (CHO-APP)
and from primary human neurons with IC50 values

in the low (1–5) micromolar range [17]. Although the
d-threo-enantiomers of these ceramide analogues have
been shown to have a high degree of specificity for
GCS (glucosylceramide synthase) [18–23], downstream
effects on membrane lipid microdomain structure,
cellular ceramide metabolism and signalling pathways
may also be involved. For example, modulation of
membrane GSL levels by PDMP and related compounds
has an impact on membrane cholesterol transport and
EGFR (epidermal growth factor receptor) signalling
[24,25]. PDMP has also been shown to inhibit ERK
(extracellular-signal-regulated kinase) phosphorylation
in neural precursor cells [26] and this is potentially
important in the current context as there is evidence that
the ERK pathway is dysregulated in AD [27–29] and that
ERK activation may regulate APP proteolysis and/or
Aβ production in vitro [30–32].
In the present study, we have investigated the
enantiomer-specific actions of PPMP and EtDO-P4 on
both cellular Aβ production and ERK signalling. We also
directly assess the impact that ERK inhibitors and siRNA
(small interfering RNA)-mediated silencing of GCS has
on cellular Aβ production.

MATERIALS AND METHODS
Materials
Synthetic ceramide analogues PDMP, d-PPMP and lPPMP were purchased from Matreya. d/l-EtDO-P4 was
synthesized as described previously [20]. The d- and
l-EtDO-P4 enantiomers were purified by preparative
normal phase HPLC using a Lux 5 μm Cellulose-2 AXIA
packed chiral 250 mm×21.2 mm column (Phenomenexa).
An Agilent 1100 HPLC system was used with a mobile
phase hexane/propan-2-ol/diethylamine (85:15:0.1, by
vol.), a flow rate of 10 ml/min and UV detection at
220 nm. d-EtDO-P4 eluted at 25 min and was collected
from the column and dried under vacuum before use in
experiments. The γ -secretase inhibitor DAPT (N-[N(3,5-difluorophenacetyl)-l-alanyl]-(S)-phenylglycine tbutyl ester) and the MAPK (mitogen-activated protein
kinase) pathway inhibitors PD98059 (2-(2-amino-3methoxyphenyl)-4H-1-benzopyran-4-one) and U0126
(1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]
butadiene) were purchased from Sigma. Purified leech
(Macrobdella decora) ceramide glycanase (EC 3.2.1.123)
was from V-Labs. Cell culture medium and additives
were obtained from Invitrogen unless stated otherwise.
All organic solvents were of analytical grade and were
purchased from Ajax Finechem. All other reagents
were purchased through standard commercial suppliers.

Cell culture
The CHO cell line stably expressing the human 695amino-acid isoform of APP (CHO-APP) was generated
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and maintained as described previously [33,34]. CHOAPP cells were cultured in RPMI 1640 medium containing 10 % (v/v) FBS (fetal bovine serum), 2 mM glutamine,
100 units/ml penicillin and 100 μg/ml streptomycin.
The cells were cultured in the presence of puromycin
(7.5 μg/ml) to maintain selection for the expression
plasmid. The SH-SY5Y-APP cell line was generated by
transfecting human SH-SY5Y neuroblastoma cells with
cDNA containing wild-type human APP695 cloned into
the pIRESpuro2 vector [35]. Stably transfected cells
were selected using 2 μg/ml puromycin and cultured
in RPMI 1640 medium containing 20 % (v/v) FBS,
2 mM glutamine, 100 units/ml penicillin, 100 μg/ml
streptomycin and 2 μg/ml puromycin to maintain
selection for the expression plasmid. SH-SY5Y-APP cells
were differentiated to generate a neuronal phenotype
using 10 μM all-trans-retinoic acid (R2625; Sigma) for
7 days as previously described [36]. Cells were treated
with GSL inhibitors, MAPK inhibitors or DAPT as
indicated for up to 48 h. These compounds were added to
cells in complete growth medium containing 10 % (v/v)
FBS.

MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-2H tetrazolium bromide] cell viability
assay
Cells were grown in 96-well plates (5000 cells/well) and
maintained as described above. Cytotoxicity was assessed
by incubating cells in 100 μl of medium containing
various concentrations of GSL inhibitors as indicated
along with vehicle controls (six wells per concentration).
After 48 h the culture medium was removed, and 100 μl of
medium [DMEM (Dulbecco’s modified Eagle’s medium)
and 10 % (v/v) FBS] containing 0.5 mg/ml MTT (M2128;
Sigma) was added and the cells were incubated for 1 h
at 37 ◦ C. The medium was discarded, and the cells were
dissolved in DMSO (100 μl per well) and the absorbance
of the cell lysates was measured at 550 nm. Higher
absorbace values indicate increased cell viability.

Quantification of Aβ40 and Aβ42 by ELISA
Cell culture medium was collected from CHO-APP and
SH-SY5Y-APP cells and pre-diluted into PBS at 1:100
for Aβ40 and at 1:10 for Aβ42 in preparation for Aβ
measurement by ELISA. βMark X-40 and X-42 ELISA
kits (SIG-38956-Kit and SIG-38954-Kit; Covance) were
used to quantify Aβ concentration, according to the
manufacturer’s instructions as described previously [37].

Western blotting
Cells were routinely cultured in 12-well plates, rinsed
with ice-cold PBS and lysed in lysis buffer (20 mM
Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 %
Nonidet P40, 0.5 % deoxycholate, 0.1 % SDS and
protease and phosphatase inhibitors). Bicinchoninic acid

411

protein assays were performed on lysates and equal
amounts of protein were separated by SDS/PAGE
(12 % gels) and transferred on to 0.2 μm nitrocellulose
membranes at 70 V for 20 min. Membranes were blocked
at 22 ◦ C for 2 h in PBS containing non-fat dried skimmed
milk powder and probed with the relevant antibodies at
4 ◦ C for 16 h to analyse APP using W0-2 monoclonal
antibody [34]. The W0-2 antibody recognizes an epitope
between residues 2 and 8 at the N-terminal of the Aβ
peptide sequence [38,39]. ERK signalling was assessed
by Western blotting using phospho-p44/42 MAPK
[pERK1/2 (phosphorylated ERK 1/2)] and p44/42
MAPK (ERK1/2) rabbit monoclonal antibodies at 1:5000
dilution (#4377 and #4695 respectively; Cell Signaling
Technology). Where indicated, the membranes were
stripped and re-probed for β-actin (rabbit polyclonal
1:5000; A5060; Sigma), which was used as a loading
control. Western blotting of secreted sAPPα (soluble
APPα fragment) and secreted Aβ peptides was carried out
as described previously using W0-2 monoclonal antibody
[34]. Both sAPPα and Aβ were routinely analysed
in growth medium containing 10 % (v/v) FBS after
48 h incubation either with or without the treatments
indicated. Signals were detected using ECL® (enhanced
chemiluminescence; GE Healthcare) and X-ray films.
The signal intensity was quantified using NIH ImageJ
software and the data presented as a ratio relative to nontreated cells as described previously [34].

PCR
RNA was isolated from cells using TRI Reagent
(T9424; Sigma) following the manufacturer’s protocol.
All procedures were carried out using RNase-free
reagents and quantification of total RNA was done by
using a NanoDrop ND-1000 spectrophotometer. RNA
(5 μg) was reverse transcribed into cDNA as described
previously [34,40]. Conventional PCR amplification was
carried out with 30 cycles of denaturation (95 ◦ C, 30 s),
annealing (58 ◦ C, 30 s) and extension (72 ◦ C, 30 s), and
the PCR products were visualized after electrophoresis
in 1 % agarose gels. The primers used are the following:
GCS (GenBank® accession number AF351131.1; cDNA
sequence, 141–320, 180 bp), forward, 5 -TAGCAAGCTCCCTGGTGTCT-3 ; reverse, 5 -TTCGGGTATTTTCCAAGCAG-3 ; and GAPDH (glyceraldehyde3-phosphate dehydrogenase; GenBank® accession number X52123.1; cDNA sequence, 309–456, 148 bp),
forward, 5 -GGAGAAGGCTGGGGCCCACT-3 ; reverse, 5 -GGTGGTGCAGGACGCATTGCT-3 .

siRNA inhibition of CHO-APP cell GCS
expression
Transfection of siRNA into CHO-APP cells was
performed using commercially prepared siRNA duplexes
(Invitrogen StealthTM ). The sequence targeted by the
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siRNA was selected using the BLOCK-iT RNAi
designer program (www.invitrogen.com/rnai), which
was found to be in close agreement with available
published sequences [41–43]. RNA sequences were
5 -UUAAACUGGCAACAAAGCAUUCUGA-3 ,
and 5 -UCAGAAUGCUUUGUUGCCAGUUUAA3 (Invitrogen synthesis number AF351131_stealth_880).
The siRNA was targeted to GCS (UDP-glucose ceramide glucosyltransferase, UGCG; GenBank® accession
number AF351131.1; cDNA sequence, 880–824)-specific
sequence 5 -TCACGTAGTTTCGTTTGACTAGTAA3 and a random reorganization of this sequence was
used as the control siRNA 5 -GAATATGCGTTTATACCGTGTTACT-3 . siRNA duplexes were transfected by using LipofectamineTM RNAiMAX (13778075; Invitrogen) by a forward transfection procedure
in six-well culture plates following the manufacturer’s
protocol. Transfection efficiency was confirmed by
substituting the siRNA with fluorescently labelled
BLOCK-iT reagent, supplied with the kit, using the
same transfection procedure and this confirmed >95 %
transfection efficiency was achieved as assessed by
fluorescence microscopy (results not shown).
Cell supernatants and lysates were collected and
processed for Western blot analysis as above. RNA
extraction, cDNA synthesis and quantitative real-time
PCR was performed as described previously [34,40].
Briefly, real-time PCR was carried out using an
Eppendorf Mastercycler® ep realplex Thermal Cycler
using the fluorescent dye SYBR Green (Eppendorf).
Amplification was carried out with 40 cycles of 94 ◦ C
for 15 s and 60 ◦ C for 1 min. All gene expression was
normalized to GAPDH, which served as an internal
control for the quality of RNA isolated from each cell
sample. Experiments were performed in triplicate and
at least three samples were analysed for each treatment.
The level of expression for each gene was calculated
using the comparative threshold cycle value (Ct ) value
method using the formula 2 − Ct (where Ct = Ct
sample − Ct reference) as described previously [44,45].

Cellular GSL analysis
GSL profiles of CHO-APP cells were analysed as
described previously [24]. Briefly, cells grown to
confluence in six-well plates were treated with synthetic
ceramide analogues as described above, rinsed three
times with PBS and lipids extracted in 2:1 (v/v)
chloroform/methanol. The GSL fractions were isolated
by silicic acid chromatography, and the glycan moiety
was released by ceramide glycanase addition [46]. The
GSL glycans were then fluorescently labelled with 2AA
(2-anthranilic acid) and analysed by normal phase HPLC
as described previously [24]. Total peak area units for
the glycan peaks were pooled to calculate the reduction
of cellular GSL levels after treatment with ceramide
analogues or GCS siRNA. We noted that interfering

peaks eluting in the positions of glucose and lactose
were detected in the commercial ceramide glycanase
enzyme blank conditions, and levels of GlcCer (glucosylceramide) and LacCer (lactosylceramide) were therefore
excluded from the analyses of CHO-APP GSL levels.
The principal GSLs analysed (asialo ganglioside GM2 ,
globotriaosylceramide, GM3 and globotetraosylceramide)
were identified based on their glucose unit values
by comparison with a 2-AA-labelled dextran standard
as previously described in detail [46,47]. Values were
expressed as a percentage of total GSL levels present in
mock-treated CHO-APP cells.

Statistical analysis
Unless stated otherwise, experiments were performed in
triplicate and with three experimental replicates. Results
are presented as means with S.E.M. shown by error bars.
Differences were considered significant where P < 0.05,
as determined using a two-tailed Student’s t test for
unpaired data.

RESULTS
Previous studies have shown that PDMP inhibits Aβ
production from the human SH-SY5Y neuronal cell
line by ∼ 55 % when used at a concentration of 25 μM
for 48 h [10]. We recently confirmed this finding and
showed that d-PDMP also inhibits Aβ production in
the well-characterized CHO-APP cell line [17]. In the
latter experiments, 48 h treatment of CHO-APP cells
with 15 μM d-PDMP reduced Aβ levels by ∼ 50 %
and an IC50 value of 15.8 μM was calculated for
PDMP-mediated inhibition of Aβ production [17]. Using
identical experimental conditions, we assessed whether
ERK phosphorylation may be modulated by d-PDMP.
At a concentration of 15 μM, d-PDMP inhibited Aβ
production by 44 % as predicted (Figure 1). Under these
conditions, pERK levels were also reduced by 27 % with
no change in total ERK (Figure 1). Since our previous
studies indicated that the structurally related PDMP
analogues, PPMP and EtDO-P4, were more potent antiamyloidogenic compounds that were more likely to be
useful as prototype therapeutic agents in vivo [17], we
next assessed the impact of these compounds on cellular
Aβ production and ERK activation.
Earlier studies indicated that the d-threo-enantiomers
of PDMP and structurally related compounds represent
the active forms of these GSL synthesis inhibitors [18–
23]. We therefore assessed the enantiomer-specific effects
of PPMP and EtDO-P4 on both Aβ production and
ERK activation. Consistent with previous data [17], 5 μM
d-PPMP inhibited Aβ production by 49 %, whereas lPPMP had no effect at the same concentration (Figure 2).
Cellular APP and secreted sAPPα were unaffected by
these compounds (Figure 2). In contrast, both d- and
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Figure 1 PDMP reduces Aβ
phosphorylation of ERK

production and reduces

CHO-APP cells were treated with 15 μM PDMP for 48 h. Secreted Aβ and
cellular APP (A), and total ERK and pERK (B) were measured by Western blotting.
β-Actin was used as a loading control. Absorbance measurements of the blots
are shown in the histogram (C); grey bars, control; black bars, treated. Results
∗∗
are mean +
− S.E.M. values; P < 0.01.

l-PPMP significantly inhibited ERK phosphorylation
(Figure 2). Similarly, when we assessed the d- and lthreo enantiomers of EtDO-P4 at a concentration of
1 μM, only the d-EtDO-P4 (which was the more potent
GSL synthesis inhibitor) significantly inhibited Aβ
production, whereas both d- and l-EtDO-P4 inhibited
ERK phosphorylation (Figure 3). Unexpectedly, the lEtDO-P4 that we separated from the d/l-EtDO-P4
mixture by preparative chiral HPLC (results not shown)
also reduced cellular GSL levels by 43 % (Figure 3A).
Even though the inhibition of Aβ production by the
d-enantiomers of all three ceramide analogues (PDMP,
PPMP and EtDO-P4) occurred concomitantly with
inhibition of ERK phosphorylation, this is unlikely
to represent their primary mode of anti-amyloidogenic
action since the l-enantiomers also inhibited ERK
activation without significantly reducing Aβ production.
It was also intriguing that the l-EtDO-P4-mediated
reductions in cellular GSL levels (which were less
pronounced than the GSL reduction resulting from dEtDO-P4) did not significantly reduce Aβ production.
To rule out the possibility that the enantiomer-specific
effect of PPMP on cellular Aβ production was simply
due to the concentration used, various concentrations
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Figure 2 PPMP D-enantiomer reduces Aβ production and
ERK phosphorylation, whereas PPMP L-enantiomer reduces
ERK phosphorylation without affecting Aβ production

CHO-APP cells were treated with 5 μM D- or L-PPMP for 48 h. Secreted Aβ and
sAPPα and cellular APP (A) and total ERK and pERK (B) were measured by Western
blotting. β-Actin was used as a loading control. Absorbance measurements of the
blots are shown in the histogram (C); grey bars, control; dark grey bars, D-PPMP
∗∗
treated; and black bars: L-PPMP. Results are mean +
− S.E.M. values; P < 0.01.
of both d-PPMP and l-PPMP were tested in parallel.
Since these compounds can become cytotoxic at high
concentrations, we first determined cell viability at
various inhibitor doses using the MTT assay. Consistent
with our previous data [17], cells remained ∼ 85 % viable
after 48 h treatment with 5 μM d-PPMP (Figure 4A).
Increased toxicity was detected when the concentration
of the inhibitor was raised to 10 μM or above (Figure 4A).
At PPMP concentrations above 10 μM, cells also
began to detach from the plates and therefore data
pertaining to MTT reduction and Aβ levels at 15 μM are
not quantitative and are therefore not presented herein.
The cytotoxicity profiles of both the d- and l-isomers
in the 1–10 μM range were very similar (Figure 4A).
Importantly, d-PPMP dose-dependently inhibited Aβ
generation, whereas l-PPMP did not (Figure 4). The
levels of another W0-2-positive protein of unknown
identity at a molecular mass of ∼ 15 kDa did not change
with inhibitor treatment in the 1–10 μM range, suggesting
that the impact of d-PPMP is not a generalized action on
cellular protein production.
We next investigated the enantiomer-specific inhibition
of cellular Aβ production in the SH-SY5Y-APP neuronal
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Figure 4 Dose-dependent effect of PPMP enantiomers on
cellular viability and Aβ secretion by CHO-APP cells

Figure 3 Effect of EtDO-P4 enantiomers on GSL synthesis,
Aβ production and ERK phosphorylation

CHO-APP cells were treated with 1 μM D-EtDO-P4 or L-EtDO-P4 enantiomer for
48 h. Lipids were extracted and GSL-derived glycans were analysed by normal
phase HPLC (A). Secreted Aβ and sAPPα and cellular APP (B) and total ERK
and pERK (C) were analysed by Western blotting. β-Actin was used as a loading
control. Absrobance measurements of the blots are shown in the histogram (C).
Grey bars, control; dark grey bars, EtDO-P4 L-enantiomer; black bars, EtDO-P4
∗
∗∗
D-enantiomer. Results are mean +
− S.E.M. values; P < 0.05, P < 0.01.

cell line. Both d-PPMP and l-PPMP displayed similar
cytotoxicity profiles in the neuronal cells as compared
with the CHO-APP cells (Figure 5A; cf Figure 4A).
In the neuronal cell line viability remained at ∼ 90 %
at inhibitor concentrations of 5 μM (Figure 5A).
Furthermore, only the d-enantiomer inhibited Aβ
production, whereas both the d- and l-enantiomers
inhibited ERK phosphorylation (Figure 5). In order to
determine if d-PPMP selectively inhibits either Aβ40
or Aβ42 production, we used an ELISA to quantify
these species. This indicated that the CHO-APP cell line
generates 7.5-fold more Aβ40 and 8.1-fold more Aβ42

CHO-APP cells were treated with D- and L-PPMP for 48 h at the indicated
concentrations (μM). Cytotoxicity was determined by MTT reduction and the data
were normalized to a control value set at 1.0 (A). The broken line indicates
L-PPMP (‘L’) and the solid line indicates D-PPMP (‘D’). Data are not included
for doses of 15 μM and above due to cell loss from the wells. Cell culture
supernatants were also assessed for secreted Aβ after treatment with 2.5, 5,
10 and 15 μM PPMP (B). Synthetic Aβ40 peptide (1 ng) was added as an
additional marker protein (‘Std’). An uncharacterized secreted W0-2-positive band
at ∼ 15 kDa (䊉) is also shown for the purposes of comparison as secretion
of this protein is not affected by either PPMP enantiomer at levels (1–10 μM)
that do not result in cell loss. Absorbance measurements of the Western blots
carried out in triplicate are shown in the histogram (C). Black bar, control; dark
grey bars, D-PPMP treated; and grey bars, L-PPMP. Results are mean +
− S.E.M.
values; ∗∗ P < 0.01. The mean relative levels of the uncharacterized 15 kDa
W0-2-positive band are indicated by (䊉).

than the SH-SY5Y cell lines and that in both cases the
amount of Aβ40 produced was ∼ 15-fold higher than
Aβ42 (Figure 6). Subsequent to treatment with 5 μM
d-PPMP, production of Aβ40 was reduced by 74 and
81 % in the CHO-APP and SH-SY5Y-APP cell lines
respectively, whereas Aβ42 was reduced by 38 % but
only in CHO-APP cells (Figure 6). This indicates that
the reduction in Aβ is predominantly due to reduction in
Aβ40. There were no significant reductions in Aβ when
cells were treated with l-PPMP and the ELISA data are
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Figure 6 Quantification of Aβ40 and Aβ42 species in
CHO-APP (A) and SH-SY5Y-APP (B) cell culture supernatants

Cells were treated with 5 μM PPMP enantiomers as indicated for 48 h and the
medium was assessed for Aβ40 and Aβ42 by ELISA. Experiments were performed
in triplicate and each sample was assayed in duplicate. The concentrations of
Aβ40 and Aβ42 (ng/ml) are shown in the histograms; ‘-’ light-grey bars,
control; black bars, D-PPMP treated; dark-grey bars, L-PPMP treated. Results are
∗
∗∗
mean +
− S.E.M. values; P < 0.05, P < 0.01.
Figure 5 PPMP D-enantiomer reduces neuronal Aβ production and ERK phosphorylation, whereas PPMP L-enantiomer
reduces ERK phosphorylation without affecting Aβ production

SH-SY5Y-APP cells were treated with D- and L-PPMP for 48 h at the indicated
concentrations (μM), the cytotoxicity was determined by the MTT reduction assay
and the data were normalized to a control value set at 1.0 (A). The broken
line indicates L-PPMP (‘L’), and the solid line indicates D-PPMP (‘D’). SH-SY5Y-APP
cells were treated with 5 μM D- or L-PPMP for 48 h. Secreted Aβ and sAPPα,
cellular APP and total ERK and pERK were measured by Western blotting (B).
Absorbance measurements of the blots are shown in the histogram (C); ‘-’ grey
bars, control; dark grey bars, D-PPMP treated; and black bars, L-PPMP. Results
∗
∗∗
are mean +
− S.E.M. values; P < 0.05, P < 0.01.
therefore in good agreement with the semi-quantitative
Western blot analysis.
Taken together, these experiments raise two important
issues regarding: (i) the direct role that ERK activation
may play in amyloidogenic APP processing and (ii)
the specificity of reduced cellular GSL synthesis as
a modulator of Aβ production. These issues were
addressed using alternative approaches to inhibit ERK
phosphorylation or GSL synthesis. To probe for a direct
role that ERK signalling may play in Aβ production,
CHO-APP cells were treated with two different well-

characterized MAPK pathway inhibitors, PD98059 or
U0126. Both PD98059 and U0126 strongly inhibited
pERK formation; however, Aβ production was not
suppressed (Figure 7). In fact, for reasons that remain
unknown, PD98059 stimulated Aβ production by 20 %
(Figure 7). The results from these experiments further
suggest that the inhibition of ERK activation by PDMP,
PPMP and EtDO-P4 is not likely to underlie their actions
as inhibitors of cellular Aβ production.
In a final set of experiments we assessed the impact
that inhibition of GSL synthesis using siRNA has on
both cellular Aβ production and ERK phosphorylation.
Targeting of GCS using a 40 nM concentration of siRNA
duplex for 48 h reduced GCS mRNA levels by 82 %
(Figure 8). This resulted in a 77 % decrease in CHO-APP
cellular GSL levels (Figure 8). The relative reductions in
the levels of the different GSL species were similar when
either ceramide analogues (see Supplementary Figure S1
at http://www.clinsci.org/cs/122/cs1220409add.htm) or
siRNA (Figure 8) was used to inhibit GCS. In parallel
experiments, GCS siRNA treatment of CHO-APP cells
did not result in any detectable changes in either Aβ
production or ERK phosphorylation (Figure 9). These
data indicate that reductions in cellular GSL levels alone
are not sufficient to reduce cellular Aβ production.
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Figure 7 Specific inhibition of ERK phosphorylation does
not reduce Aβ production

CHO-APP cells were treated with specific ERK phosphorylation inhibitors PD98059
(10 μM) or U0126 (5 μM). Secreted Aβ and sAPPα and cellular APP (A) and
total ERK and pERK (B) were analysed by Western blotting. β-Actin was used
as a loading control. Absorbance measurements of the Western blots are shown
in the histogram (C): grey bars, control; dark grey bars, PD98059 treated; black
∗
∗∗
bars, U0126 treated. Results are mean +
− S.E.M. values; P < 0.05, P < 0.01.

DISCUSSION
There is accumulating data to suggest that alterations in
cerebral lipid homoeostasis may be directly associated
with AD (see [48] for a review). Based on the fact
that APP is a type I membrane protein that is
proteolytically processed to form Aβ in sphingolipidenriched membrane microdomains, the possibility that
modulation of membrane lipid composition could
represent a novel means to regulate Aβ production
presents a plausible basis for AD therapeutic intervention
[9,11,49–52].
Studies from different laboratories have shown that
the ceramide analogue inhibitors of GCS that are based
on the PDMP structure inhibit Aβ production in
vitro [10,17]; however, the mechanism(s) of their antiamyloidogenic action remain to be fully elucidated. In
the present studies, we have shown that the inhibition of
ERK phosphorylation mediated by these GSL inhibitors
is not likely to contribute to their anti-amyloidogenic
actions since both d- and l-enantiomers inhibit ERK
activation, whereas only the d-enantiomers suppress
cellular Aβ production. It remains possible that the
efficacy of additional anti-amyloidogenic compounds

Figure 8 siRNA knockdown of GCS reduces CHO-APP cellular
GSL levels

CHO-APP cells were transfected with GCS siRNA duplex (40 nM) or scrambled
siRNA for 48 h. RNA and lipids were extracted from replicate cell culture plates
for real-time PCR and HPLC analyses. Relative expression data for both CGS mRNA
and cellular GSL levels are shown in the histogram (A); grey bars, scrambled
∗
siRNA; black bars, GCS siRNA. Results mean +
− S.E.M. values (n = 3); P < 0.05,
∗∗∗
P < 0.001. Representative HPLC chromatograms are shown (B). The dextran
ladder ‘2AA dextran’ was used to calculate glucose unit (GU) values and thus
identify the cellular GSL species. The enzyme blank samples ‘Enzyme blank’
indicate the presence of a contaminating peak in the position of LacCer. The
lower two chromatograms indicate HPLC separation of glycans from mock and GCS
siRNA-treated samples. Note that the y -axis for the globotriaosylceramide peak
is expanded 15 times to allow visualization. GA2, asialo ganglioside GM2 ; Gb3,
globotriaosylceramide; Gb4, globotetraosylceramide; GM3, ganglioside GM3 .
is related to modulation of the ERK pathway, and
in associated studies (see Supplementary Figure S2 at
http://www.clinsci.org/cs/122/cs1220409add.htm) we
found that the inhibition of Aβ production by lovastatin
[a competitive inhibitor of HMG-CoA (3-hydroxy3-methylglutaryl-CoA) reductase (a cholesterollowering drug)] was correlated with reduced ERK
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Figure 9 Endogenous GCS knockdown has little impact on
Aβ production and ERK phosphorylation

CHO-APP cells were transfected with GCS siRNA duplex (40 nM) or scrambled siRNA
for 48 h. Secreted Aβ and sAPPα and cellular APP (A) and total ERK and pERK
(B) were measured by Western blotting with β-actin used as a loading control.
Absorbance measurements of the Western blots are shown in the histogram (C);
grey bars, control; black bars, GCS-siRNA. Results are mean +
− S.E.M. values.
phosphorylation (whereas the γ -secretase inhibitor
DAPT did not alter ERK signalling). Since ERK
signalling is clearly dysregulated in AD [28,29],
normalization of this pathway may still represent a
therapeutic option (for PDMP-related compounds and
other more specific ERK modulators), however, this does
not appear to be the pathway by which these ceramide
analogues inhibit Aβ production.
A recent study indicates that inhibition of the ERK
pathway has no impact on cellular sAPPα secretion [53].
This finding is in agreement with the present study that
shows inhibition of ERK activation by PDMP, PPMP
and EtDO-P4, and their enantiomers, where applicable,
does not significantly alter cellular sAPPα secretion.
It is noteworthy, however, that some aspects of αsecretase activity may be modulated by ERK activation
in a substrate-specific manner as ERK1 does control
α-secretase-mediated processing of the cellular prion
protein [54].
Previous research suggests that raft-associated GSLs
promote amyloidogenic processing of APP via regulation
of BACE and γ -secretase activities [9,11]. We therefore
speculated that the inhibition of Aβ production by
the ceramide analogue GCS inhibitors we used would be
mirrored by siRNA silencing of GCS. Intriguingly,
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the ∼ 75 % reduction in cellular GSL levels that was
induced by GCS knockdown had no impact on Aβ
production. This may indicate that the d-enantiomers
of the ceramide analogues we have used have additional
actions (either direct or indirect) on APP processing
that remain to be discovered and that inhibition of GSL
synthesis alone (i.e. using siRNA targeting) may only
be efficacious in situations where membrane GSL levels
are increased above their physiological concentrations.
Alternatively, it may be that modulation of very specific
neutral or charged GSL species that are not highly
expressed in the in vitro systems we have used is
required to reveal an impact on Aβ production. Future
studies would be required to examine the effect that the
numerous individual GSL species may have on cellular
APP processing. We acknowledge that specific GSLs play
other roles (in addition to potentially regulating APP
processing) that may impact on AD pathology. As a case
in point, ganglioside GM1 plays a crucial role in regulating
the transition of monomeric Aβ to neurotoxic oligomers
and the use of compounds such as d-EtDO-P4 to suppress this activity would represent a viable therapeutic target that is independent of its impact on APP processing.
It is noteworthy that d-threo-EtDO-P4 has been
administered successfully in long-term studies in
mice [21,55]. In addition, a potentially relevant GCS
inhibitor {Eliglustat tartrate, (1R,2R)-octanoic acid [2(2 ,3 -dihydro-benzo [1,4] dioxin-6 -yl)-2-hydroxy-1pyrrolidin-1-ylmethyl-ethyl]-amide-l-tartaric acid salt,
formerly Genz-112638} is currently in human clinical
trials to treat Type 1 Gaucher disease where it has
been shown to reduce plasma GlcCer and GM3 levels
in association with improvement in a number of clinical
manifestations of the disease [56–59]. The data from
our group and others suggest that such GCS inhibitors
may also be worth investigating as anti-amyloidogenic
agents in relevant AD amyloidogenic mouse models and
potentially in the human AD setting.
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Figure S1 Inhibition of CHO-APP GSL levels by D-PDMP

CHO-APP cells were incubated for 48 h in the absence (upper profile, ‘CHO
control’) or presence (lower profile, ‘CHO PPMP(D) 5 μM’) of 5 μM D-PPMP.
Lipids were extracted and GSL glycans were analysed by HPLC as described in
the legend to Figure 8. Gb3, globotriaosylceramide; Gb4, globotetraosylceramide;
GM3, ganglioside GM3 .

Figure S2 Influence of lovastatin and DAPT (two antiamyloidogenic non-GSL-modifying compounds) on ERK activation

CHO-APP cells were treated with lovastatin (1 μM) or DAPT (1 μM) for 48 h,
and secreted Aβ and sAPPα and cellular APP and total ERK and pERK (A) were
measured by Western blotting with β-actin used as a loading control. Absorbance
measurements of the Western blots are shown in the histograms (B): grey bars,
control; dark grey bars, lovastatin treated; and black bars, DAPT treated. Results
∗
∗∗
are mean +
− S.E.M. values; P < 0.05, P < 0.01.
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